Noguchi H
Sumitomo Pharmaceuticals Research Center, Discovery Research Laboratories II.
Nihon Rinsho. 1997 Jun;55(6):1549-56.
Monoclonal antibodies (MAbs) have been extensively developed for treating autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and intestinal bowl diseases. Recombinant DNA technology made it possible to manufacture chimeric and humanized MAbs, resulting in lower antigenicity, longer half-life in serum and higher biological activities compared to the original murine MAbs. Here, chimeric and humanized MAbs under clinical investigations in the field of autoimmune diseases are reviewed. At this time, non-deleting type of anti-CD4 MAb and anti-TNF alpha MAb have an attractive attention because of their excellent efficacy in the clinical trials. Although deleting type of anti-CD4 MAb failed to show the efficacy in double-blind phase III trials reproducibly, it should be re-evaluated on the administration dosage and duration. In the near future, MAbs to adhesion molecules and co-stimulatory molecules will be studied in clinics.
单克隆抗体（MAb）已被广泛开发用于治疗自身免疫性疾病，如类风湿性关节炎、多发性硬化症和肠道疾病。重组DNA技术使嵌合和人源化单克隆抗体的制造成为可能，与原始鼠单克隆抗体相比，其抗原性更低、血清半衰期更长且生物活性更高。在此，对自身免疫性疾病领域正在进行临床研究的嵌合和人源化单克隆抗体进行综述。目前，非清除型抗CD4单克隆抗体和抗TNFα单克隆抗体因其在临床试验中的优异疗效而备受关注。尽管清除型抗CD4单克隆抗体在双盲III期试验中未能重现疗效，但应重新评估给药剂量和疗程。在不久的将来，针对黏附分子和共刺激分子的单克隆抗体将在临床上进行研究。
